))
ποΈ Episode 32: SGLT2 vs Kidney Stones: A Surprising Win
Manage episode 478124859 series 3659512
Content provided by Brilliant Board Review & CME, Brilliant Board Review, and CME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brilliant Board Review & CME, Brilliant Board Review, and CME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
π§ͺ Key Findings:
Cohort study: SGLT2 inhibitors led to significantly lower rates of nephrolithiasis compared to GLP-1 RAs.
Mechanism: increased urinary flow and uric acid excretion.
π’ Stats:
NNT = 20 for prevention.
NNT = 5 for recurrent stone formers.
𧩠Clinical Takeaway:
Another bonus benefit of SGLT2 inhibitors.
May sway decision in diabetics prone to stones.
HCTZ no longer holds the same weight in stone prevention.
Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.
Chapters
1. ποΈ Episode 32: SGLT2 vs Kidney Stones: A Surprising Win (00:00:00)
2. SGL2s and Kidney Stone Prevention (00:00:22)
3. Comparing SGL2s vs GLP-1s Study Results (00:01:13)
4. Debunking Hydrochlorothiazide Myths (00:02:20)
45 episodes
Share
